MX351635B - Anticuerpos monoclonales frente a progastrina y sus usos. - Google Patents
Anticuerpos monoclonales frente a progastrina y sus usos.Info
- Publication number
- MX351635B MX351635B MX2012004400A MX2012004400A MX351635B MX 351635 B MX351635 B MX 351635B MX 2012004400 A MX2012004400 A MX 2012004400A MX 2012004400 A MX2012004400 A MX 2012004400A MX 351635 B MX351635 B MX 351635B
- Authority
- MX
- Mexico
- Prior art keywords
- progastrin
- methods
- monoclonal antibodies
- antibodies
- monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G01N33/57535—
-
- G01N33/57585—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25262509P | 2009-10-16 | 2009-10-16 | |
| PCT/EP2010/006329 WO2011045080A2 (en) | 2009-10-16 | 2010-10-15 | Monoclonal antibodies to progastrin and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012004400A MX2012004400A (es) | 2012-06-27 |
| MX351635B true MX351635B (es) | 2017-10-23 |
Family
ID=43086711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004400A MX351635B (es) | 2009-10-16 | 2010-10-15 | Anticuerpos monoclonales frente a progastrina y sus usos. |
Country Status (42)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008076454A1 (en) | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
| PL3421493T3 (pl) * | 2009-10-16 | 2024-04-29 | Progastrine Et Cancers S.À R.L. | Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| US20150071912A1 (en) * | 2010-03-24 | 2015-03-12 | Centre National De La Recherche Scientifique (Cnrs) | Prophylaxis of colorectal and gastrointestinal cancer |
| SG187544A1 (en) * | 2010-07-26 | 2013-03-28 | Servier Lab | Methods and compositions for liver cancer therapy |
| US8785603B2 (en) * | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
| EP2715364A1 (en) | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
| CN105517572B (zh) * | 2013-07-05 | 2019-05-31 | 华盛顿大学商业中心 | 用于治疗癌症的中和可溶性mic的单克隆抗体 |
| US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
| ES2843546T3 (es) * | 2014-04-18 | 2021-07-19 | The Research Foundation Of The State Univ Of New York | Anticuerpos humanizados anti-antígeno-TF |
| WO2016066671A1 (en) | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
| WO2017048629A1 (en) * | 2015-09-15 | 2017-03-23 | The Scripps Research Institute | Antibodies for generating anti-inflammatory macrophage and related uses |
| PL3397964T3 (pl) * | 2015-12-31 | 2022-02-07 | Progastrine Et Cancers S.À R.L. | Kompozycje i sposoby do wykrywania i leczenia raka jajnika |
| MA43550A (fr) * | 2015-12-31 | 2018-11-07 | Syncerus S A R L | Compositions et procédés d'évaluation du risque d'apparition d'un cancer |
| ES2899360T3 (es) | 2015-12-31 | 2022-03-11 | Progastrine Et Cancers S A R L | Composiciones y procedimientos para detectar y tratar cáncer gástrico |
| AU2018246368B2 (en) * | 2017-03-30 | 2023-02-09 | Ecs-Progastrin Sa | Compositions and methods for detecting lung cancer |
| KR102317805B1 (ko) * | 2017-03-30 | 2021-10-27 | 이씨에스-프로가스트린 에스에이 | 전립선암을 검출하기 위한 조성물 및 방법 |
| PL3720879T3 (pl) * | 2017-12-05 | 2022-09-12 | Progastrine Et Cancers S.À R.L. | Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu |
| CN112004560A (zh) | 2017-12-08 | 2020-11-27 | Ecs生物识别系统有限公司 | 癌症诊断中的放射性标记的前胃液素 |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| KR102699073B1 (ko) * | 2018-02-27 | 2024-08-26 | 이씨에스-프로가스트린 에스에이 | 면역치료요법용 생체표지자로서 프로가스트린 |
| TWI793238B (zh) * | 2018-12-27 | 2023-02-21 | 偉喬生醫股份有限公司 | 體外檢測生物樣品之胃源性蛋白的方法及套組 |
| US20220372125A1 (en) * | 2019-10-02 | 2022-11-24 | Aslan Pharmaceuticals Pte. Ltd. | Antigen Specific Binding Domains and Antibody Molecules |
| CN112062846A (zh) * | 2020-04-27 | 2020-12-11 | 杭州博茵生物技术有限公司 | 一种g-17单克隆抗体及其应用 |
| CN115785273B (zh) * | 2021-09-10 | 2023-10-31 | 东莞市朋志生物科技有限公司 | 一种抗胃蛋白酶原i的抗体及其应用 |
| CN115724949A (zh) * | 2022-12-12 | 2023-03-03 | 郑州伊美诺生物技术有限公司 | 一种鼠源lgG单克隆抗体及其制备方法、应用 |
| CN116143920A (zh) * | 2022-12-30 | 2023-05-23 | 南京岚煜生物科技有限公司 | 胃泌素17的单克隆抗体及其细胞株的制备方法和应用 |
| EP4509528A1 (en) * | 2023-08-16 | 2025-02-19 | Barrelman Biosciences LLC | Monoclonal antibodies against veterinary progastrin-like molecules and their uses |
| CN117567611B (zh) * | 2023-11-22 | 2024-05-14 | 艾维可生物科技有限公司 | 抗成熟型胃泌素17的单克隆抗体及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1794586B1 (en) * | 2004-09-22 | 2013-01-30 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
| ES2727306T3 (es) * | 2006-05-22 | 2019-10-15 | Inst Nat Sante Rech Med | Inhibidores de progastrina en el tratamiento del cáncer de colon |
| WO2008076454A1 (en) | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| PL3421493T3 (pl) * | 2009-10-16 | 2024-04-29 | Progastrine Et Cancers S.À R.L. | Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania |
| US20150071912A1 (en) * | 2010-03-24 | 2015-03-12 | Centre National De La Recherche Scientifique (Cnrs) | Prophylaxis of colorectal and gastrointestinal cancer |
| SG187544A1 (en) * | 2010-07-26 | 2013-03-28 | Servier Lab | Methods and compositions for liver cancer therapy |
-
2010
- 2010-10-15 PL PL18185172.6T patent/PL3421493T3/pl unknown
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko not_active Ceased
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/en not_active Ceased
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 PH PH1/2012/500711A patent/PH12012500711B1/en unknown
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/en active Active
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active Active
- 2010-10-15 ES ES18185172T patent/ES2973217T3/es active Active
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 SM SM20180628T patent/SMT201800628T1/it unknown
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/en active Active
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
- 2010-10-15 CA CA2777691A patent/CA2777691C/en active Active
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 BR BR112012008818-1A patent/BR112012008818B1/pt active IP Right Grant
- 2010-10-15 HR HRP20181645TT patent/HRP20181645T1/hr unknown
-
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
-
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
-
2017
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
-
2018
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
-
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
-
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351635B (es) | Anticuerpos monoclonales frente a progastrina y sus usos. | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| BR112012016820A2 (pt) | Metodos para tratamento de cancer de seio | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| MX370597B (es) | Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| BR112015003757A2 (pt) | anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| EA201591801A1 (ru) | Лекарственные конъюгаты антител | |
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| CL2011000931A1 (es) | Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer. | |
| MX352373B (es) | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
| HK1206610A1 (en) | Fully human antibodies that bind to vegfr2 | |
| AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies | |
| EA201270315A1 (ru) | Новые формы полициклического соединения | |
| TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. | |
| TR200606118U (tr) | İki parça entübasyon tüpü sabitleme aparatı | |
| BR112014028507A2 (pt) | anticorpos cd33 e uso dos mesmos para tratar câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: LES LABORATOIRES SERVIER |
|
| FG | Grant or registration |